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Please note: 
Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications and conference abstracts of 
phase III trials, assessing the safety and efficacy of the drugs of interest. 
At the very end of each chapter we have provided a table containing the prioritization criteria and a 
drop-down field to apply the provided criteria. 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 24th prioritisation (September 2015), 7 were filtered out of 191 identified drugs and were 
sent to prioritisation. Of these, 2 drugs were ranked as ‘highly relevant’ by the expert panel, 4 as 
‘relevant’ and 1 as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for 
example, abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all drugs are provided in the following table. 
 
 
No.  
 
Filtered Drugs – 23
rd
 prioritisation 2
nd
 quarter 2015 
 
Overall category 
1. Afatinib (Giotrif®, Gilotrif®, BIBW 2992) as second-line 
treatment of patients with advanced squamous cell carcinoma of 
the lung 
Relevant 
2. Necitumumab (IMC-11F8, LY3012211) as first-line therapy in 
patients with stage IV squamous NSCLC 
Relevant 
3. Standard chemotherapy with or without bevacizumab (Avastin®) 
for women with newly diagnosed ovarian cancer 
Highly relevant 
4. Docetaxel (Taxotere®, Docefim®) in metastatic hormone-
sensitive prostate cancer 
Relevant 
5. Everolimus (Afinitor®, RAD-001) as first-line treatment for 
patients with HER2-positive advanced breast cancer 
Highly relevant 
6. Oxaliplatin (Eloxatin®) added to fluorouracil-based preoperative 
chemoradiotherapy and postoperative chemotherapy of locally 
advanced rectal cancer 
Not relevant 
7. Vosaroxin (QinprezoTM, AG-7352, SPC-595, SNS 595, 
Voreloxin) in patients with first relapsed or refractory acute 
myeloid leukaemia 
Relevant 
 
 
Horizon Scanning in Oncology    
 
Ergänzende Informationen zu den Arzneistoffen für Priorisierung XXIV – HSS Onkologie Seite 3 von 5 
1 Ovarian Cancer  
1.1 Standard chemotherapy with or without bevacizumab 
(Avastin®) for women with newly diagnosed ovarian cancer 
Overview 
Drug Description 
 
a recombinant monoclonal antibody that binds to vascular endothelial 
growth factor  (VEGF) and inhibits the binding to its receptors (VEGFR-1 
and VEGFR-2) 
 
Incidence in 
Austria 
9.0 per 100,000 women per year, 683 newly diagnosed women per year 
Approval 
status for 
this 
indication 
EMA 
- in combination with carboplatin and paclitaxel is indicated for the 
front-line treatment of adult patients with advanced (International 
Federation of Gynecology and Obstetrics (FIGO) stages III B, III C 
and IV) epithelial ovarian, fallopian tube, or primary peritoneal 
cancer since July 2014 
FDA - 
Phase III results: 
The Lancet (2015) Vol.16, Issue: 8 Pages 928-936 (Oza et al.) Standard chemotherapy with or 
without bevacizumab for women with newly diagnosed ovarian cancer (ICON 7): overall survival 
results of a phase 3 randomised trial. 
Background  
The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer 
with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high 
risk of disease progression. We report the final overall survival results of the trial. 
 
Methods  
ICON7 was an international, phase 3, open-label, randomised trial undertaken at 263 centres in 11 
countries across Europe, Canada, Australia and New Zealand. Eligible adult women with newly 
diagnosed ovarian cancer that was either high-risk early-stage disease (International Federation of 
Gynecology and Obstetrics [FIGO] stage I–IIa, grade 3 or clear cell histology) or more advanced 
disease (FIGO stage IIb–IV), with an Eastern Cooperative Oncology Group performance status of 0–2, 
were enrolled and randomly assigned in a 1:1 ratio to standard chemotherapy (six 3-weekly cycles of 
intravenous carboplatin [AUC 5 or 6] and paclitaxel 175 mg/m² of body surface area) or the same 
chemotherapy regimen plus bevacizumab 7·5 mg per kg bodyweight intravenously every 3 weeks, 
given concurrently and continued with up to 12 further 3-weekly cycles of maintenance therapy. 
Randomisation was done by a minimisation algorithm stratified by FIGO stage, residual disease, 
interval between surgery and chemotherapy, and Gynecologic Cancer InterGroup group. The primary 
endpoint was progression-free survival; the study was also powered to detect a difference in overall 
survival. Analysis was by intention to treat. This trial is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN91273375. 
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Results  
Between Dec 18, 2006, and Feb 16, 2009, 1528 women were enrolled and randomly assigned to 
receive chemotherapy (n=764) or chemotherapy plus bevacizumab (n=764). Median follow-up at the 
end of the trial on March 31, 2013, was 48·9 months (IQR 26·6–56·2), at which point 714 patients had 
died (352 in the chemotherapy group and 362 in the bevacizumab group). Our results showed 
evidence of non-proportional hazards, so we used the difference in restricted mean survival time as 
the primary estimate of effect. No overall survival benefit of bevacizumab was recorded (restricted 
mean survival time 44·6 months [95% CI 43·2–45·9] in the standard chemotherapy group vs. 45·5 
months [44·2–46·7] in the bevacizumab group; log-rank p=0·85). In an exploratory analysis of a 
predefined subgroup of 502 patients with poor prognosis disease, 332 (66%) died (174 in the standard 
chemotherapy group and 158 in the bevacizumab group), and a significant difference in overall 
survival was noted between women who received bevacizumab plus chemotherapy and those who 
received chemotherapy alone (restricted mean survival time 34·5 months [95% CI 32·0–37·0] with 
standard chemotherapy vs. 39·3 months [37·0–41·7] with bevacizumab; log-rank p=0·03). However, in 
non-high-risk patients, the restricted mean survival time did not differ significantly between the two 
treatment groups (49·7 months [95% CI 48·3–51·1]) in the standard chemotherapy group vs. 48·4 
months [47·0–49·9] in the bevacizumab group; p=0·20). An updated analysis of progression-free 
survival showed no difference between treatment groups. During extended follow-up, one further 
treatment-related grade 3 event (gastrointestinal fistula in a bevacizumab-treated patient), three grade 
2 treatment-related events (cardiac failure, sarcoidosis, and foot fracture, all in bevacizumab-treated 
patients), and one grade 1 treatment-related event (vaginal haemorrhage, in a patient treated with 
standard chemotherapy) were reported. 
 
Conclusion 
Bevacizumab, added to platinum-based chemotherapy, did not increase overall survival in the study 
population as a whole. However, an overall survival benefit was recorded in poor-prognosis patients, 
which is concordant with the progression-free survival results from ICON7 and GOG-218, and 
provides further evidence towards the optimum use of bevacizumab in the treatment of ovarian 
cancer. 
2 Breast Cancer 
2.1 Everolimus (Afinitor®, RAD-001) as first-line treatment for 
patients with HER2-positive advanced breast cancer 
Overview 
Drug Description an inhibitor of the mammalian target of rapamycin (mTOR) protein 
Incidence in 
Austria 
 
76.2 per 100,000 women per year; 5,423 newly diagnosed women per 
year 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Phase III results: 
The Lancet (2015) Vol.16, Issue: 7, Pages 816-829 (Hurvitz et al.) Combination of everolimus with 
trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast 
cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial 
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Background  
mTOR inhibition reverses trastuzumab resistance via the hyperactivated PIK/AKT/mTOR pathway due 
to PTEN loss, by sensitising PTEN-deficient tumours to trastuzumab. The BOLERO-1 study assessed 
the efficacy and safety of adding everolimus to trastuzumab and paclitaxel as first-line treatment for 
patients with HER2-positive advanced breast cancer. 
 
Methods  
In this phase 3, randomised, double-blind trial, patients were enrolled across 141 sites in 28 countries. 
Eligible patients were aged 18 years or older, with locally assessed HER2-positive advanced breast 
cancer, with Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, who had not 
received previous trastuzumab or chemotherapy for advanced breast cancer within 12 months of 
randomisation, had measurable disease as per Response Evaluation Criteria in Solid Tumors 
(RECIST) or bone lesions in the absence of measurable disease, without previous systemic treatment 
for advanced disease except endocrine therapy. Patients were randomly assigned (2:1) with an 
interactive voice and web response system to receive either 10 mg everolimus once a day orally or 
placebo plus weekly trastuzumab intravenously at 4 mg/kg loading dose on day 1 with subsequent 
weekly doses of 2 mg/kg of each 4 week cycle plus paclitaxel intravenously at a dose of 80 mg/m² on 
days 1, 8, and 15 of each 4 week cycle. Randomisation was stratified according to previous use of 
trastuzumab and visceral metastasis. Patients and investigators were masked to the assigned 
treatments. Identity of experimental treatments was concealed by use of everolimus and placebo that 
were identical in packaging, labelling, appearance, and administration schedule. The two primary 
objectives were investigator-assessed progression-free survival in the full study population and in the 
subset of patients with hormone receptor-negative breast cancer at baseline; the latter was added 
during the course of the study, before unmasking based on new clinical and biological findings from 
other studies. All efficacy analyses were based on the intention-to-treat population. Enrolment for this 
trial is closed and results of the final progression-free survival analyses are presented here. This trial is 
registered with ClinicalTrials.gov, number NCT00876395. 
 
Results  
Between Sept 10, 2009, and Dec 16, 2012, 719 patients were randomly assigned to receive 
everolimus (n=480) or placebo (n=239). Median follow-up was 41·3 months (IQR 35·4–46·6). In the 
full population, median progression-free survival was 14·95 months (95% CI 14·55–17·91) with 
everolimus versus 14·49 months (12·29–17·08) with placebo (hazard ratio 0·89, 95% CI 0·73–1·08; 
p=0·1166). In the HR-negative subpopulation (n=311), median progression-free survival with 
everolimus was 20·27 months (95% CI 14·95–24·08) versus 13·08 months (10·05–16·56) with 
placebo (hazard ratio 0·66, 95% CI 0·48–0·91; p=0·0049); however, the protocol-specified significance 
threshold (p=0·0044) was not crossed. The most common adverse events with everolimus were 
stomatitis (314 [67%] of 472 patients in the everolimus group vs. 77 [32%] of 238 patients in the 
placebo group), diarrhoea (267 [57%] vs. 111 [47%] patients), and alopecia (221 [47%] vs. 125 [53%]). 
The most frequently reported grade 3 or 4 adverse events in the everolimus group versus the placebo 
group were neutropenia (117 [25%] vs. 35 [15%]), stomatitis (59 [13%] vs. three [1%]), anaemia (46 
[10%] vs. six [3%]) and diarrhoea (43 [9%] vs. 10 [4%]) On-treatment adverse event-related deaths 
were reported in 17 (4%) patients in the everolimus group and none in the placebo group. 
 
Conclusion 
Although progression-free survival was not significantly different between groups in the full analysis 
population, the 7·2 months prolongation we noted with the addition of everolimus in the HR-negative, 
HER2-positive population warrants further investigation, even if it did not meet prespecified criteria for 
significance. The safety profile was generally consistent with what was previously reported in 
BOLERO-3. Proactive monitoring and early management of adverse events in patients given 
everolimus and chemotherapy is crucial. 
 
 
